Skin infiltrating NK cells in cutaneous T-cell lymphoma are increased in number and display phenotypic alterations partially driven by the tumor.

CD8+ T cells CTCL NK cells cutaneous lymphoma mycosis fungoides tumor environment

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 17 02 2023
accepted: 25 07 2023
medline: 12 9 2023
pubmed: 11 9 2023
entrez: 11 9 2023
Statut: epublish

Résumé

Cutaneous T-cell lymphomas (CTCL) are characterized by focal infiltration of malignant T cell clones in solitary skin lesions. Many CTCL patients experience an indolent disease, but some progress to advanced disease with high fatality. We hypothesized that natural killer (NK) cells participate in local control of tumor growth in CTCL skin. Immunohistochemistry and flow cytometry analysis of the density, localization, phenotype and function of NK cells in twenty-nine fresh or formalin-fixed skin biopsies from twenty-four CTCL patients and twenty-three biopsies from twenty healthy controls highlighted higher numbers of CD56

Identifiants

pubmed: 37691935
doi: 10.3389/fimmu.2023.1168684
pmc: PMC10485839
doi:

Substances chimiques

Granzymes EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1168684

Informations de copyright

Copyright © 2023 Scheffschick, Nenonen, Xiang, Winther, Ehrström, Wahren-Herlenius, Eidsmo and Brauner.

Déclaration de conflit d'intérêts

HB has received honoraria from participating in advisory boards of Kyowa Kirin in 2019 and 2022. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Immunol. 2020 Feb 21;11:275
pubmed: 32153582
J Virol. 2014 Aug;88(15):8349-54
pubmed: 24829350
Front Immunol. 2020 May 19;11:868
pubmed: 32508818
Am J Hematol. 2019 Sep;94(9):1027-1041
pubmed: 31313347
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
J Clin Oncol. 2001 Dec 1;19(23):4322-9
pubmed: 11731515
J Clin Oncol. 2020 Jan 1;38(1):20-28
pubmed: 31532724
J Clin Oncol. 2010 Nov 1;28(31):4730-9
pubmed: 20855822
Front Immunol. 2019 May 31;10:1205
pubmed: 31214177
Arch Dermatol. 2003 Jul;139(7):857-66
pubmed: 12873880
Cancer Res. 2007 Jun 15;67(12):5594-9
pubmed: 17575122
Eur J Immunol. 2021 Mar;51(3):672-681
pubmed: 33231295
Clin Cancer Res. 2019 Jul 15;25(14):4443-4454
pubmed: 31010835
Leuk Res. 2009 Sep;33(9):1166-9
pubmed: 19423163
Cancer. 2012 Dec 1;118(23):5830-9
pubmed: 22674564
J Immunol. 2015 Mar 15;194(6):2942-53
pubmed: 25681335
Int J Mol Sci. 2023 Feb 01;24(3):
pubmed: 36769064
Lung Cancer. 2002 Jan;35(1):23-8
pubmed: 11750709
J Invest Dermatol. 2005 Dec;125(6):1273-8
pubmed: 16354199
Cell Metab. 2016 Nov 8;24(5):657-671
pubmed: 27641098
Blood. 2004 Dec 15;104(13):4142-9
pubmed: 15328153
J Immunother Cancer. 2020 May;8(1):
pubmed: 32461348
Leukemia. 2005 Jan;19(1):69-76
pubmed: 15526027
J Clin Invest. 2020 Mar 2;130(3):1185-1198
pubmed: 31770109
Front Immunol. 2019 Jun 04;10:1242
pubmed: 31214193
Front Immunol. 2017 Jul 24;8:892
pubmed: 28791027
Curr Opin Chem Eng. 2018 Mar;19:9-20
pubmed: 29623254
Nat Rev Cancer. 2020 Aug;20(8):437-454
pubmed: 32581320
Blood. 2007 Sep 15;110(6):1713-22
pubmed: 17540844
Front Immunol. 2013 Dec 09;4:422
pubmed: 24367364
Cell. 2019 Jun 13;177(7):1701-1713.e16
pubmed: 31155232
Transl Oncol. 2021 Jan;14(1):100930
pubmed: 33186888
Am J Clin Dermatol. 2002;3(3):193-215
pubmed: 11978140
J Immunol Res. 2018 Sep 3;2018:6248590
pubmed: 30255106
Hematol Oncol. 2019 Jun;37 Suppl 1:43-47
pubmed: 31187534
J Immunol. 2006 Apr 1;176(7):4331-6
pubmed: 16547270
Clin Exp Immunol. 2014 Oct;178(1):79-85
pubmed: 24894428
Cancer Immunol Immunother. 2018 Apr;67(4):675-689
pubmed: 29392336
Arthritis Res Ther. 2013 Oct 01;15(5):R139
pubmed: 24286519
Lung Cancer. 2012 Jul;77(1):38-45
pubmed: 22387007
PLoS One. 2011;6(9):e22842
pubmed: 21909397
Front Immunol. 2019 Sep 24;10:2278
pubmed: 31616440

Auteurs

Andrea Scheffschick (A)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Julia Nenonen (J)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Mengmeng Xiang (M)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Anna H Winther (AH)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden.

Marcus Ehrström (M)

Department of Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden.

Marie Wahren-Herlenius (M)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
The Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.

Liv Eidsmo (L)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
LEO Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

Hanna Brauner (H)

Division of Rheumatology, Department of Medicine, Solna and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Department of Dermatology, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH